Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Skin cancer, neuroendocrine carcinoma (Merkel cell)
Stage/Subtype:  recurrent neuroendocrine carcinoma of the skin
Trial Type:  Treatment
Results 1-11 of 11 for your search:
Start Over
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Sapanisertib in Treating Patients with Recurrent or Metastatic Merkel Cell Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-223, NCI-2016-00695, NCT02514824
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: SCRX001-006, NCI-2016-01071, NCT02709889
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PEN-221-001, NCI-2017-00043, NCT02936323
Cabozantinib-S-Malate in Treating Patients with Recurrent or Metastatic Merkel Cell Carcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-490, NCI-2014-00941, NCT02036476
Pembrolizumab in Treating Patients with Advanced Merkel Cell Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CITN-09, NCI-2014-00848, MK-3475, NCT02267603
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S1609, NCI-2016-01041, NCT02834013
RRx-001 in Small, Non-small Cell Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RRx001-211-01, NCI-2016-01889, NCT02489903
Talimogene Laherparepvec and Nivolumab in Treating Patients with Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10057, NCI-2016-01804, NCT02978625
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: TTI-621-02, NCI-2016-01486, NCT02890368
Veliparib, Capecitabine, and Temozolomide in Treating Patients with Advanced, Metastatic, and Recurrent Neuroendocrine Tumor That Cannot Be Removed by Surgery
Status: Not yet active
Phase: Phase I
Type: Treatment
Age: 19 and over
Trial IDs: VICC GI 14134, NCI-2016-01044, NCT02831179
Start Over